Heartflow
HeartFlow is a medical technology company revolutionizing precision heart care by combining advanced imaging and artificial intelligence to provide non-invasive cardiac tests. Their flagship product, the HeartFlow FFRCT Analysis, offers unprecedented visualization of coronary arteries, enabling physicians to make informed treatment decisions without invasive procedures. With over 250,000 patients served and adoption in more than 950 hospitals worldwide, HeartFlow is positioned as a leader in the cardiology space, backed by a robust body of clinical evidence and a strong intellectual property portfolio.
Heartflow
HeartFlow is a medical technology company revolutionizing precision heart care by combining advanced imaging and artificial intelligence to provide non-invasive cardiac tests. Their flagship product, the HeartFlow FFRCT Analysis, offers unprecedented visualization of coronary arteries, enabling physicians to make informed treatment decisions without invasive procedures. With over 250,000 patients served and adoption in more than 950 hospitals worldwide, HeartFlow is positioned as a leader in the cardiology space, backed by a robust body of clinical evidence and a strong intellectual property portfolio.
TL;DR
Company: Heartflow — AI-driven non-invasive cardiac diagnostics (FFRCT)
Founded / HQ: Founded ~2010; Mountain View, California
Scale: 250,000+ patients served; adoption in 950+ hospitals
Flagship product: HeartFlow Analysis (FFRCT); also Plaque Analysis and Roadmap Analysis
Latest financing: $98M convertible notes (Mar 26, 2025); Series F $215M (Apr 6, 2023)
Company Overview
Problem Domain
Cardiology diagnostics — non-invasive assessment and decision support for coronary artery disease
Founded
2010
Industry
Medical technology / Healthtech
Tech Stack
Funding Track Record
$215,000,000
$98,000,000
Included new investment from Fidelity Management & Research Company and participation from existing investors
Investor Signal
“Includes participation from institutional investors such as Bain Capital Life Sciences, Janus Henderson, Baillie Gifford, Capricorn Investment Group, Hayfin Capital Management, HealthCor, Martis Capital, USVP, Wellington Management, and Fidelity Management & Research Company”